Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Junker K, Zillmann R, Rüssel C, Hellmis E, Suttmann H, Janssen M, Marin J, Hübner A, Mathers M, Gleißner J, Scheffler M, Feyerabend S, Telle J, Klier J, Stöckle M.
Ohlmann CH, et al. Among authors: jaschke m.
Prostate Cancer Prostatic Dis. 2023 Dec;26(4):812. doi: 10.1038/s41391-023-00682-2.
Prostate Cancer Prostatic Dis. 2023.
PMID: 37253975
Free PMC article.
No abstract available.